PBLS

27.4400.67%
BL

Barbara L. Weber

Independent Non-Employee Director

Dr. Barbara L. Weber, M.D., is Member of Supervisory Board of Itm Isotopen Technologien MÜNchen Aktiengesellschaft from May 1, 2025. Dr. Weber is Independent Non-Employee Director of Parabilis Medicines, Inc. from October 25, 2018. Dr. Weber Co-founded Tango Therapeutics Inc. and served as its President and Chief Executive Officer since March 2017 until January 08, 2026 and served as its Director since March 2017 until August 03, 2026 and served as Executive Chairman of the Board since January 08, 2026 until August 03, 2026 and also served as Chairperson. Dr. Weber serves as a Director of OPY Acquisition Corp. I since October 2021. Dr. Weber served as Venture Partner at Third Rock Ventures, LLC since joining in 2015 till March 2022. Dr. Weber was an Entrepreneur-in-Residence at the firm. She joined the firm in 2015. She has been a Director at Fog Pharmaceuticals, Inc. since October 25, 2018 and served as its Member of Scientific Advisory Board until 2022. She was an Independent Director of Revolution Medicines Inc. since April 2018 until June 18, 2025. She was involved in the launch of Tango Therapeutics. She is a Member of honorary societies such as the American Association of Physicians and the American Society for Clinical Investigation. Dr. Weber served as an Interim Chief Medical Officer of Neon Therapeutics Inc. until January 10, 2017. She worked at Novartis, where she held the position of Senior Vice President and Global Head of Oncology Translational Medicine from 2009 to February 2015, Vice President, Oncology, GSK from 2005 to 2009 and Professor, Medicine and Genetics, University of Pennsylvania from 1994 to 2005. In this role, she was responsible for early clinical and translational scientific functions, including trial design and execution, implementation of patient selection strategies and continuation of translational support through full development. Dr. Weber served as Vice President of three groups at GlaxoSmithKline, including Global Biomarkers, Oncology Discovery and Translational Medicine and Cancer Metabolism Drug Discovery. Until 2005, she was a Professor of Medicine and Genetics at The University of Pennsylvania School of Medicine, Heading a clinical and translational research program in cancer genetics and the UPenn Cancer Center Breast Cancer program. She served as President in 2005 at American Society for Clinical Investigation. Dr. Weber has served on various scientific advisory boards and on the Board of Directors of both the American Society of Clinical Oncology and the American Association of Cancer Research. She has experience working in oncology research, in which time she is widely published and received numerous academic and research awards for her work. She has served as a scientific and medical advisor to FogPharma since its founding. Dr. Weber holds an M.D. from University of Washington School of Medicine (1978-1982) and a B.S. in Chemistry, University of Washington (1974-1978). She completed her residency in Internal Medicine at Yale University School of Medicine and her fellowship in Medical Oncology at the Dana-Farber Cancer Instituter Cancer Institute.

Positions